XML 58 R44.htm IDEA: XBRL DOCUMENT
v3.19.2

Collaborative Agreements (Details) - USD ($) |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
May 06, 2016 | Dec. 29, 2015 | Dec. 24, 2018 | Sep. 30, 2017 | Sep. 25, 2017 | Jul. 24, 2017 | May 26, 2017 | Feb. 28, 2017 | Aug. 31, 2016 | Jul. 27, 2016 | Mar. 31, 2016 | Dec. 31, 2015 | Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | Dec. 31, 2017
Collaborative Agreements (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock newly issued, value |  |  |  |  |  |  |  |  |  |  |  |  | $ 694,219 | $ 80,000 | $ 80,000 | $ 5,850,000
Outstanding balance |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,550,000
Collaborative Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Description of payment settlement |  | Upfront payment shall upon the signing of this BioLite Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week. Upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week. At the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months. Upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week. At the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months. Upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week. |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount received from BriVision |  | $ 100,000,000 |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |
Upfront payments |  | $ 3,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of payments under co-development agreement |  | 3.50% |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |
Milestone payments to BioLite in cash | $ 2,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock newly issued, value | $ 900,000 |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |
Common stock newly issued, shares | 562,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share price | $ 1.60 |  |  |  |  |  |  | $ 2.0 |  |  |  |  |  |  |  |
Licensing rights |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |
Accounts payable |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,000,000 |  | $ 15,000,000 |
Research and development expense |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |
Agreement, terms |  | This BioLite Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term. |  |  |  |  |  |  |  |  |  |  |  |  |  |
Co-Dev Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount received from BriVision |  |  |  | $ 3,000,000 |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  | 450,000
Percentage of payments under co-development agreement |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  | 15.00% |
Licensing rights |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000 |
Accounts payable |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,000,000 |
Company cash payments |  |  |  | $ 3,000,000 |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |
Co-Dev agreement, description |  |  | The Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene's Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549. |  |  |  |  |  |  |  |  |  |  |  |  |
BHK Co-Development Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Description of payment settlement |  |  |  |  |  |  |  |  |  | Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment At the completion of first phase II clinical trial: $1 million, or 10% of total payment At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment |  |  |  |  |  |
Upfront payments |  |  |  |  |  |  |  |  |  | $ 1,000,000 |  | $ 1,000,000 |  |  |  |
Percentage of payments under co-development agreement |  |  |  |  |  |  |  |  |  | 10.00% |  | 10.00% |  |  |  |
Milestone payments to BioLite in cash |  |  |  |  |  |  |  |  | $ 31,649,000 | $ 10,000,000 |  |  |  |  |  |
Common stock newly issued, value |  |  |  |  |  |  |  |  | $ 1,000,000 |  |  | $ 10,000,000 |  |  |  |
Milestone payments royalty percentage |  |  |  |  |  |  |  |  | 12.00% |  |  |  |  |  |  |
Collaborative Agreements, description |  |  |  |  |  |  |  |  |  |  |  | The Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK. | In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of March 31, 2019 and 2018, the Company has not earned the royalty under the BHK Collaborative Agreements. |  |  |
Collaborative Arrangement One [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of payments under co-development agreement |  |  |  |  |  |  |  |  |  |  | 6.50% |  |  |  |  |
Milestone payments to BioLite in cash |  |  |  |  |  |  |  | $ 650,000 |  |  |  |  |  |  |  |
Common stock newly issued, value |  |  |  |  |  |  |  | $ 5,850,000 |  |  |  |  |  |  |  |
Common stock newly issued, shares |  |  |  |  |  |  |  | 2,925,000 |  |  |  |  |  |  |  |
Share price |  |  |  |  |  |  |  | $ 2.0 |  |  |  |  |  |  |  |
Accounts payable |  |  |  |  |  |  |  |  |  |  | $ 6,500,000 |  |  |  |  |
Research and development expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,000,000

X
- Definition Co-Dev agreement description. + References No definition available. + Details
Name: | abvcd_CoDevAgreementDescription
Namespace Prefix: | abvcd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | abvcd_CollaborativeAgreementTextualAbstract
Namespace Prefix: | abvcd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreements, description + References No definition available. + Details
Name: | abvcd_CollaborativeAgreementsDescription
Namespace Prefix: | abvcd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payments. + References No definition available. + Details
Name: | abvcd_MilestonePayments
Namespace Prefix: | abvcd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments royalty percentage. + References No definition available. + Details
Name: | abvcd_MilestonePaymentsRoyaltyPercentage
Namespace Prefix: | abvcd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of payments under co-development agreement. + References No definition available. + Details
Name: | abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement
Namespace Prefix: | abvcd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of upfront payments which are paid during the term of agreement. + References No definition available. + Details
Name: | abvcd_UpfrontPayments
Namespace Prefix: | abvcd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount for accounts payable to related parties. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.17) -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910 + Details
Name: | us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(11)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(2)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 + Details
Name: | us-gaap_DueFromRelatedPartiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount payable to related parties classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(3),(4)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.17) -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 + Details
Name: | us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of other research and development expense. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash payments related to participation costs. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 926 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6473203&loc=d3e55336-107963 + Details
Name: | us-gaap_PaymentsForParticipationLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Description of the effects of any change in the method of establishing the terms of a related party transaction for example, pricing terms, from that used in the preceding period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 + Details
Name: | us-gaap_RelatedPartyTransactionEffectsOfAnyChangeInMethodOfEstablishingTerms
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of the terms and manner of settlement of the related party transaction. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 + Details
Name: | us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvcd_CodevelopmentagreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvcd_BHKCoDevelopmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvcd_CollaborativeArrangementOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |